The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
Open accessAbstract
The rising incidence and persistent dismal 5-year overall survival of pancreatic ductal adenocarcinoma (PDAC) highlight the need for new effective systemic therapies. Immunotherapy has shown significant benefits in solid organ tumors, but has thus far been disappointing in the treatment of PDAC. There have been several promising preclinical studies, but translation into the clinic has proved to be challenging. This is likely a result of PDAC's complex immunosuppressive tumor microenvironment that acts to insulate the tumor against an effective cytotoxic immune response. Here, we summarize the mechanisms of immunosuppression within the PDAC tumor microenvironment and provide an up-to-date review of completed and ongoing clinical trials using various immunotherapy strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1×
“The histologic hallmark of PDAC is a heavily desmoplastic microenvironment that accounts for approximately 70% of tumor tissue, with increased fibrosis shown to be an independent prognostic factor.(33,34) Pancreatic stellate cells (PSCs; activated PSCs have been referred to as cancer-associated fibroblasts [CAFs]) pro…”
BackgroundPD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 2×
“The marked desmoplasia results in elevated interstitial fluid pressure limiting perfusion and diffusion of small molecule therapies secondary to intratumoral small vessel collapse.(36) The associated hypoperfusion produces an overall hypoxic environment resulting in a Treg-mediated CD81 T-cell inhibition.”
BackgroundFeig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 1×
“In addition, the use of a CXCR4 antagonist increased CD81 T-cell accumulation and acted synergistically with anti–PD-L1 antibody to decrease tumor burden in preclinical models.(41) CAFs are capable of diminishing CTL function through secretion of soluble substances such as interleukin-10 (IL-10), transforming growth f…”
BackgroundThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Self-citationRoyal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,257
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M., Hawkins, W. G., Shapiro, I. M., Weaver, D. T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4123 · Cited by 1,060
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990 · cited 1×
“The PDAC TME is characterized by a robust immune infiltrate, which comprises nearly 50% of its cellular component and is largely composed of CD451 bone marrow–derived immune cells.(16,22,45) PDAC induces an altered state of myelopoiesis, recruitment, and repolarization of these cells to promote their accumulation and…”
BackgroundBayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947
Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 943
Self-citationImmune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P., Upstill-Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.014 · Cited by 845
Hiraoka, N., Onozato, K., Kosuge, T., & Hirohashi, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0369 · Cited by 831
Nywening, T. M., Wang-Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Cusworth, B. M., Toriola, A. T., Nieman, R. K., Worley, L. A., Yano, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00078-4 · Cited by 807
Self-citationZhu, Y., Herndon, J. M., Sojka, D. K., Kim, K.-W., Knolhoff, B. L., Zuo, C., Cullinan, D. R., Luo, J., Bearden, A. R., Lavine, K. J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.014 · Cited by 801
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770
O’Reilly, E. M., Oh, D.-Y., Dhani, N., Renouf, D. J., Lee, M. A., Sun, W., Fisher, G., Hezel, A., Chang, S.-C., Vlahovic, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1588 · Cited by 767
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733 · cited 1×
“The associated hypoperfusion produces an overall hypoxic environment resulting in a Treg-mediated CD81 T-cell inhibition.(37) Preclinical work targeting hyaluronic acid (HA) through enzymatic degradation resulted in normalization of interstitial fluid pressure and permanent remodeling of the TME, leading to doubled OS…”
BackgroundTseng, D., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Fathman, J. W., Fernhoff, N. B., Seita, J., Inlay, M. A., Weiskopf, K., Miyanishi, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305569110 · Cited by 657
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653
Sanford, D. E., Belt, B. A., Panni, R. Z., Mayer, A., Deshpande, A. D., Carpenter, D., Mitchem, J. B., Plambeck-Suess, S. M., Worley, L. A., Goetz, B. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0525 · Cited by 613
Self-citationLe, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Böttcher, J. P., & Reis e Sousa, C. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.09.001 · Cited by 607
Ene–Obong, A., Clear, A. J., Watt, J., Wang, J., Fatah, R., Riches, J. C., Marshall, J. F., Chin–Aleong, J., Chelala, C., Gribben, J. G., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.025 · Cited by 579
Bockorny, B., Semenisty, V., Macarulla, T., Borazanci, E., Wolpin, B. M., Stemmer, S. M., Golan, T., Geva, R., Borad, M. J., Pedersen, K. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0880-x · Cited by 557
Adoptive T cell therapy for cancer in the clinic
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32446 · Cited by 553
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Lutz, E. R., Wu, A. A., Bigelow, E., Sharma, R., Mo, G., Soares, K., Solt, S., Dorman, A., Wamwea, A., Yager, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0027 · Cited by 550
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
Van Cutsem, E., Tempero, M. A., Sigal, D., Oh, D.-Y., Fazio, N., Macarulla, T., Hitre, E., Hammel, P., Hendifar, A. E., Bates, S. E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00590 · Cited by 499
Nywening, T. M., Belt, B. A., Cullinan, D. R., Panni, R. Z., Han, B. J., Sanford, D. E., Jacobs, R. C., Ye, J., Patel, A. A., Gillanders, W. E., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-313738 · Cited by 489
Self-citationBruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., Gorjestani, S., Liudahl, S. M., Truitt, M., Olson, P., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0827 · Cited by 486
Beatty, G. L., Torigian, D. A., Chiorean, E. G., Saboury, B., Brothers, A., Alavi, A., Troxel, A. B., Sun, W., Teitelbaum, U. R., Vonderheide, R. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1320 · Cited by 456
Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., & Linehan, D. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1746 · Cited by 450
Self-citationBroadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444 · cited 2×
“Tumor-associated macrophages (TAMs), in contrast to MDSCs, are mature cells derived from either the bone marrow or resident tissue macrophages.(48,49) Elevated peripheral and intratumoral levels of inflammatory myeloid cells have been associated with poor clinical outcomes.”
BackgroundErkan, M., Michalski, C. W., Rieder, S., Reiser–Erkan, C., Abiatari, I., Kolb, A., Giese, N. A., Esposito, I., Friess, H., & Kleeff, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.05.006 · Cited by 424
Thistlethwaite, F. C., Gilham, D. E., Guest, R. D., Rothwell, D. G., Pillai, M., Burt, D. J., Byatte, A. J., Kirillova, N., Valle, J. W., Sharma, S. K., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2034-7 · Cited by 406
McAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J. C., Lankapalli, R. H., Zhang, H., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.014 · Cited by 405 · cited 1×
“Mutated KRAS, resulting in constitutive activation, is found in 92% of pancreatic cancer(20) and is associated with several downstream effects including production of granulocyte-macrophage colonystimulating factor (GM-CSF), leading to recruitment of immunosuppressive myeloid cells(21); promotion, formation, and maint…”
BackgroundDaley, D., Mani, V. R., Mohan, N., Akkad, N., Ochi, A., Heindel, D. W., Lee, K. B., Zambirinis, C. P., Pandian, G. S. B., Savadkar, S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4314 · Cited by 381
Jang, J.-E., Hajdu, C. H., Liot, C., Miller, G., Dustin, M. L., & Bar-Sagi, D. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.062 · Cited by 372
Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F. M., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & Pasca di Magliano, M. (2017) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 337
Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity
Stromnes, I. M., Brockenbrough, J. S., Izeradjene, K., Carlson, M. A., Cuevas, C., Simmons, R. M., Greenberg, P. D., & Hingorani, S. R. (2014) · Gut · doi:10.1136/gutjnl-2013-306271 · Cited by 331
O'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., Cabanski, C. R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30532-5 · Cited by 307
The Immune Revolution: A Case for Priming, Not Checkpoint
Vonderheide, R. H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.008 · Cited by 293
Qian, Z. R., Rubinson, D. A., Nowak, J. A., Morales-Oyarvide, V., Dunne, R. F., Kozak, M. M., Welch, M. W., Brais, L. K., Da Silva, A., Li, T., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3420 · Cited by 260
Self-citationLe, D. T., Picozzi, V. J., Ko, A. H., Wainberg, Z. A., Kindler, H., Wang-Gillam, A., Oberstein, P., Morse, M. A., Zeh, H. J., Weekes, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2992 · Cited by 260
Chao, T., Furth, E. E., & Vonderheide, R. H. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0188 · Cited by 246
Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
Jiang, H., Hegde, S., & DeNardo, D. G. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2003-1 · Cited by 242
Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
Fan, J.-Q., Wang, M.-F., Chen, H.-L., Shang, D., Das, J. K., & Song, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01151-3 · Cited by 230
Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia
Lee, K. E., Spata, M., Bayne, L. J., Buza, E. L., Durham, A. C., Allman, D., Vonderheide, R. H., & Simon, M. C. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0822 · Cited by 227
McCracken, M. N., Cha, A. C., & Weissman, I. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2520 · Cited by 224
Ramanathan, R. K., Lee, K. M., McKolanis, J., Hitbold, E., Schraut, W., Moser, A. J., Warnick, E., Whiteside, T., Osborne, J., Kim, H., et al. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0581-1 · Cited by 217
Hardacre, J. M., Mulcahy, M., Small, W., Talamonti, M., Obel, J., Krishnamurthi, S., Rocha-Lima, C. S., Safran, H., Lenz, H.-J., & Chiorean, E. G. (2013) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-2064-6 · Cited by 208
KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment
Dias Carvalho, P., Guimarães, C. F., Cardoso, A. P., Mendonça, S., Costa, Â. M., Oliveira, M. J., & Velho, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2084 · Cited by 202
Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies
Panni, R. Z., Herndon, J. M., Zuo, C., Hegde, S., Hogg, G. D., Knolhoff, B. L., Breden, M. A., Li, X., Krisnawan, V. E., Khan, S. Q., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau9240 · Cited by 201
Stromnes, I. M., Schmitt, T. M., Hulbert, A., Brockenbrough, J. S., Nguyen, H. N., Cuevas, C., Dotson, A. M., Tan, X., Hotes, J. L., Greenberg, P. D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.022 · Cited by 200
Byrne, K. T., Betts, C. B., Mick, R., Sivagnanam, S., Bajor, D. L., Laheru, D. A., Chiorean, E. G., O'Hara, M. H., Liudahl, S. M., Newcomb, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1047 · Cited by 199
Noel, M., O’Reilly, E. M., Wolpin, B. M., Ryan, D. P., Bullock, A. J., Britten, C. D., Linehan, D. C., Belt, B. A., Gamelin, E. C., Ganguly, B., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00830-3 · Cited by 199
Self-citationGM-CSF Mediates Mesenchymal–Epithelial Cross-talk in Pancreatic Cancer
Waghray, M., Yalamanchili, M., Dziubinski, M., Zeinali, M., Erkkinen, M., Yang, H., Schradle, K. A., Urs, S., Pasca Di Magliano, M., Welling, T. H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0947 · Cited by 197
T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma
Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D., & Hingorani, S. R. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0322 · Cited by 197
Wedén, S., Klemp, M., Gladhaug, I. P., Møller, M., Eriksen, J. A., Gaudernack, G., & Buanes, T. (2011) · International Journal of Cancer · doi:10.1002/ijc.25449 · Cited by 183
Lack of immunoediting in murine pancreatic cancer reversed with neoantigen
Evans, R. A., Diamond, M. S., Rech, A. J., Chao, T., Richardson, M. W., Lin, J. H., Bajor, D. L., Byrne, K. T., Stanger, B. Z., Riley, J. L., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88328 · Cited by 180
Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis
Lin, J. H., Huffman, A. P., Wattenberg, M. M., Walter, D. M., Carpenter, E. L., Feldser, D. M., Beatty, G. L., Furth, E. E., & Vonderheide, R. H. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190673 · Cited by 178
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
Bailey, P., Chang, D. K., Forget, M.-A., Lucas, F. A. S., Alvarez, H. A., Haymaker, C., Chattopadhyay, C., Kim, S.-H., Ekmekcioglu, S., Grimm, E. A., et al. (2016) · Scientific Reports · doi:10.1038/srep35848 · Cited by 170
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
Beatty, G. L., Li, Y., & Long, K. B. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1270208 · Cited by 163
Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
Zippelius, A., Schreiner, J., Herzig, P., & Müller, P. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0226 · Cited by 145
The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma
Wang, L. M., Silva, M. A., D’Costa, Z., Bockelmann, R., Soonawalla, Z. F., Liu, S. K., O’Neill, E. E., Mukherjee, S., McKenna, W. G., Muschel, R. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6770 · Cited by 127
Tempero, M. A., Oh, D., Tabernero, J. M., Reni, M., Cutsem, E. V., Hendifar, A. E., Waldschmidt, D., Starling, N., Bachet, J., Chang, H. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.070 · Cited by 123
Hurwitz, H. I., Cutsem, E. V., Bendell, J. C., Hidalgo, M. M., Li, C., Salvo, M. G., Macarulla, T. M., Sahai, V., Sama, A. R., Greeno, E. W., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0580-2 · Cited by 115
CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer
Bengsch, F., Knoblock, D. M., Liu, A., McAllister, F. M., & Beatty, G. L. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2053-4 · Cited by 114
Massó-Vallés, D., Jauset, T., Serrano, E., Sodir, N. M., Pedersen, K., Affara, N. I., Whitfield, J. R., Beaulieu, M.-È., Evan, G. I., Elias, L., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2852 · Cited by 113
Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
Abou‐Alfa, G. K., Chapman, P. B., Feilchenfeldt, J. W., Brennan, M. F., Capanu, M., Gansukh, B., Jacobs, G., Levin, A. R., Neville, D. A., Kelsen, D. P., et al. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181e84b1f · Cited by 111
Kondo, H., Hazama, S., Kawaoka, T., Yoshino, S., Yoshida, S., Tokuno, K., 高島, 元., Ueno, T., Hinoda, Y., & Oka, M. (2008) · PubMed · Cited by 110
Hewitt, D. B., Nissen, N., Hatoum, H., Musher, B., Seng, J., Coveler, A. L., Al-Rajabi, R., Yeo, C. J., Leiby, B., Banks, J., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004669 · Cited by 110
Tassi, E., Gavazzi, F., Albarello, L., Senyukov, V., Longhi, R., Dellabona, P., Doglioni, C., Braga, M., Carlo, V. D., & Protti, M. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6595 · Cited by 107
Poschke, I. C., Faryna, M., Bergmann, F., Floßdorf, M., Lauenstein, C., Hermes, J., Hinz, U., Hank, T. P., Ehrenberg, R., Volkmar, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1240859 · Cited by 106
Komar, H. M., Serpa, G., Kerscher, C., Schwoegl, E., Mace, T. A., Jin, M. L., Yang, M.-C., Chen, C., Bloomston, M., Ostrowski, M. C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01973-0 · Cited by 88
The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF
Behrens, M. E., Grandgenett, P. M., Bailey, J. M., Singh, P. K., Yi, C.-H., Yu, F., & Hollingsworth, M. A. (2010) · Oncogene · doi:10.1038/onc.2010.327 · Cited by 81
Pancreatic cancer-associated stellate cells
Mace, T. A., Bloomston, M., & Lesinski, G. B. (2013) · OncoImmunology · doi:10.4161/onci.24891 · Cited by 68
O’Hara, M. H., Messersmith, W. A., Kindler, H. L., Zhang, W., Pitou, C., Szpurka, A. M., Wang, D., Peng, S.-B., Vangerow, B., Khan, A. A., et al. (2020) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2019.0018 · Cited by 55
Manji, G. A., Wainberg, Z. A., Krishnan, K., Giafis, N., Udyavar, A. R., Quah, C. S., Scott, J., Berry, W., DiRenzo, D. M., Gerrick, K. Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.404 · Cited by 28
Matsui, H., Hazama, S., Sakamoto, K., Shindo, Y., Kanekiyo, S., Nakashima, M., Matsukuma, S., Tokuhisa, Y., Iida, M., Suzuki, N., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000880 · Cited by 23
O’Hara, M. H., O'Reilly, E. M., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Rahma, O. E., Fisher, G. A., Lyman, J. P., Cabanski, C. R., Karakunnel, J. J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4019 · Cited by 23
Rasco, D. W., Bendell, J. C., Wang‐Gillam, A., Park, W., O'Reilly, E. M., Zhou, L., Galkin, A., Carter, L., Nickle, D. C., Li, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3085 · Cited by 10
Cited by
Neoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
Xiao, Z., Todd, L., Huang, L., Noguera-Ortega, E., Lu, Z., Huang, L., Kopp, M., Li, Y., Pattada, N., Zhong, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40850-5 · Cited by 272
Natu, J., & Nagaraju, G. P. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216382 · Cited by 73
Metadata
- Authors
- Ullman, N. A., Burchard, P. R., Dunne, R. F., & Linehan, D. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-08-20
- Volume
- 40
- Issue
- 24
- Pages
- 2789-2805
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4285491989
- Cited by
- 302
- References
- 104
- FWCI
- 21.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.